数据日期 2026-10-29 · 生成时间 2026-10-29 06:03
研究问题
Apolipoprotein E (APOE) is the major lipid transport protein in the central nervous system (CNS), where it maintains cholesterol homeostasis, supports synaptic integrity, and facilitates amyloid-β (Aβ) clearance [1].
方法
Participants were selected based on the availability of both blood and CSF primary and secondary glycosylation measurements, imaging data, and complete basic demographic information.；This yielded 75 healthy control (HC) and 56 MCI participants, all of whom were included in every downstream analysis (glycosylation, imaging, and survival), with no further exclusions.；All participants underwent cognitive and functional assessments, including the Mini–Mental State Examination (MMSE), Montreal Cognitive Assessment (MoCA), and Functional Activities Questionnaire (FAQ).；Moreover, white matter hyperintensities and hippocampal volume were also measured to predict the risk of AD in individuals with normal cognition or MCI.
核心结论
No significant group differences were observed in age (p = 0.150), gender distribution (p = 0.818) and education duration (p = 0.337).；Cognitive assessments revealed statistically lower MMSE and MoCA scores in the MCI group (p = 0.004, p < 0.001, respectively), accompanied by a reduced functional capacity as measured by the FAQ (p < 0.001).；The frequency of APOE4 carriers was not significantly higher in the MCI group (p = 0.377). ‖ 结论：Given the small sample size, the lack of assay replication, multiple testing, and the absence of independent cut-off validation, these findings should be considered hypothesis-generating and require confirmation in larger longitudinal cohorts.
局限
Residual confounding therefore cannot be excluded, and future studies with comprehensive vascular risk profiling and longitudinal imaging are needed to clarify the specificity of these associations.；In donor-level analysis, MGAT1 did not reach significance and showed state/region heterogeneity, and there was no robust APOE4 dose effect.；Future studies integrating paired CSF glycosylation and transcriptomic data from the same individuals, together with experimental validation, are needed to test this model.
对本项目的价值
★★☆☆☆ 脑老化是最大未满足需求，也是终点最难量化的领域；biomarker 与认知读数选择最敏感。队列：ADNI；设计 前瞻队列、横断面。
全文来源
PMC JATS 全文（正文 33,867 字符，已过标题/DOI 逐字归属校验）
原文题录
- 英文标题：CSF APOE Secondary Glycosylation Predicts Cognitive Decline in Mild Cognitive Impairment.
- 期刊与标识：Biomedicines · PMID 42940012 · DOI 10.3390/biomedicines14102206**
A 级证据分级：A 级（同行评议人体研究）
本文属人体研究证据，但需注意：观察性或小样本干预的结论不等于已证实临床获益；效应量与长期安全性仍需更大规模、更长随访的试验验证。
关于本文的文献来源：本站依据 IMA 知识库「五刊监控·深度文献卡片」撰写，依据已获取的期刊全文（方法、样本量与结论已回到原文核对）；未能获取全文的同批条目另行标注「摘要级」，全程未做任何数值推算补全。